The COVID-19 pandemic has rebounded in many places recently. Nucleic acid testing is a critical cornerstone of the COVID-19 response and has become the current standard for the diagnosis of COVID-19 infections.

At first, 10 mixed samples in one tube for batch testing is commonly used to reduce the cost and improve the efficiency of nucleic acid testing. Recently, the National Health Commission issued a Notice on the Issuance of Testing Technical Specification of Novel Coronavirus for 20-in-1 Mixed Sampling in response to the large-scale population COVID-19 pandemic testing demands.

MGI has upgraded the performance of MGISTP-7000 High-throughput Automated Sample Transfer Processing Systems to further improve nucleic acid testing capacity and reduce the working pressure of medical staff. MGISTP-7000 can be perfectly compatible with the 20-30ml sample tube to achieve 20 samples mixed in 1 tube for batch testing to provide urgent instrumental support for large-scale nucleic acid testing.

MGISTP-7000 can automate the whole process of tube decapping, tube recapping, barcode identification, liquid transfer, and tube recycling. The upgraded MGISTP-7000 can load original 20-30ml samples tubes with caps by replacing the gripper and tube decapping module and placing new sample G rack.

Since the outbreak of the pandemic, MGI has been fighting on the front line to support the global COVID-19 efforts. MGI is committed to upgrading our innovative platforms to standardize a diagnostic testing lab with higher data capacity and automation for large-scale nucleic acid detection and has independently developed a wide range of lab automation system, including MGISTP-7000 High-throughput Automated Sample Transfer Processing System, MGISP-960 High-throughput Automated Sample Preparation System, MGISP-NE384 High-throughput Automated Nucleic Acid Extractor. MGI will continue its mission to develop more innovative life science tools for future healthcare to benefit all.